Janssen Search
Search results
Ben Wiegand, Ph.D.
BEN WIEGAND, PH.D. GLOBAL HEAD WORLD WITHOUT DISEASE ACCELERATOR As Global Head of the World Without Disease Accelerator (WWDA), Ben Wiegand, Ph.D. leads a team focused on catalyzing a paradigm shift from disease care to health care through novel ...
Careers with Janssen Immunology
Welcome, we're glad you're here! Our mission is to redefine treatments for immune diseases by delivering transformational and accessible therapies and regimens to patients. To get there, we need to push the boundaries of science and creativity – ...
ASCO GU 2021
Thank you for visiting the Janssen Oncology newsroom to learn more about our research that will be presented at the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium (ASCO GU). Janssen Oncology has 12 company-sponsored ...
Kevin Wildenhaus, Ph.D.
KEVIN WILDENHAUS, PH.D. BEHAVIORAL SCIENCE LEAD WORLD WITHOUT DISEASE ACCELERATOR As Behavioral Science Lead for the World Without Disease Accelerator (WWDA), Kevin leads behavioral science efforts across the WWDA portfolio. His responsibility within the ...
Artificial Intelligence Machine Based Analytics Computer Vision
By leveraging both artificial intelligence (AI) and machine learning (ML) analysis techniques, image analysis has become a cornerstone of healthcare Data Science and Digital Health by helping to solve real-world challenges. Artificial Intelligence, ...
Hematologic Malignancies (Blood Cancers)
Hematologic Malignancies (Blood Cancers) There has been significant progress in the treatment of people diagnosed with blood cancers over the past 50 years. Our leadership has advanced transformative therapies for hematologic malignancies, and we are ...
Janssen Seeks European Commission Approval of a New Indication for CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) for the Earlier Treatment of Patients with Relapsed and Refractory Multiple Myeloma
May 25, 2023 Belgium Application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, which evaluated the safety profile and efficacy of cilta-cel in the treatment of patients who received one to three prior lines of ...
European Commission Approves Reduced Dosing Frequency for Janssen’s Bispecific Antibody TECVAYLI®▼ (teclistamab)
Aug 18, 2023 Belgium Teclistamab, the first BCMA-targeting bispecific antibody to receive approval in Europe, maintained deep and durable responses, with reduced onset of Grade 3 or higher infections, in eligible patients with relapsed and refractory ...
Providing Patients with Prostate Cancer and Blood Cancer More Time
Providing Patients with Prostate Cancer and Blood Cancer More Time September is Prostate Cancer and Blood Cancer Awareness Month, and while these diseases may not seem to have much in common, in fact they share inseparable characteristics. Despite ...
Neuroscience
"With neuroscience as part of Janssen's origin story, we are focused on brain health, actively searching for solutions for all the people living with disorders of the nervous system." Bill Martin, Ph.D. GLOBAL THERAPEUTIC AREA HEAD The ...